IDEAYA Biosciences Gets Fast-Track Designation for IDE161 for Breast Cancer
By Chris Wack
IDEAYA Biosciences said Wednesday that the U.S. Food and Drug Administration has granted fast-track designation to its development program investigating IDE161 for the treatment of adult patients having advanced or metastatic hormone receptor positive, Her2- breast cancer with germline or somatic BRCA 1/2 mutations.
IDE161 is the company's potent and selective inhibitor of poly glycohydrolase in both BRCA1/2-mutant breast and ovarian cancers.
Fast track is a U.S. FDA process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
IDEAYA's Phase 1 first-in-human clinical trial is evaluating the safety, tolerability, pharmacokinetic and pharmacodynamic properties and preliminary efficacy of IDE161 in patients having solid tumors with homologous recombination deficiency.
IDEAYA is targeting program updates for IDE161 in the fourth quarter of 2023. The company owns or controls all commercial rights in IDE161, subject to certain economic obligations under its exclusive, worldwide license with Cancer Research UK and University of Manchester.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 27, 2023 06:28 ET (10:28 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks